Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28381171 | 0.98 | PTGS2 (0.38) | PTGS2CA1CA2PTGS1LMNA | |
| SCHEMBL28382229 | 0.91 | PTGS2 (0.35) | PTGS2CA1CA2PTGS1LMNA | |
| Magnesium Chloride Anhydrous SCHEMBL29107334 | 0.91 | PTGS2 (0.35) | PTGS2CA1CA2PTGS1LMNA | |
| SCHEMBL27961977 | 0.87 | CYP3A4 (0.38) | PTGS2CA1CA2LMNATP53 | |
| SCHEMBL2290039 | 0.78 | AR (0.33) | — | |
| SCHEMBL4796005 | 0.76 | — | — | |
| SCHEMBL3096012 | 0.72 | CA2 (0.50) | PTGS2CA1CA2PTGS1LMNA | |
| SCHEMBL6956929 | 0.72 | PREP (0.34) | LMNATP53CYP3A4HPGDALDH1A1 | |
| SCHEMBL1550969 | 0.70 | CA2 (0.35) | CA1CA2ALOX15ALDH1A1 | |
| SCHEMBL5100912 | 0.70 | KDM4E (0.33) | CA1CA2ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423739-B | Improved enantioselective hydrogenation of 4-substituted 1, 2-dihydroquinolines in the presence of chiral iridium catalysts and additives | 拜耳公司 | 2024-06-25 | — | — | CN | claimed |
| CN-118146274-A | PNN tridentate ligand with face chirality and phosphine chirality and application thereof in free radical asymmetric functionalization and related reaction | 武汉大学 | 2024-06-07 | — | — | CN | claimed |
| WO-2024100405-A1 | CATALYTIC HYDROGENATION PROCESS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2024-05-16 | — | — | WO | claimed |
| CN-114621286-B | Fluoroalkyl-substituted trivalent organic phosphine compound, and preparation method and application thereof | 中山大学 | 2024-02-27 | — | — | CN | claimed |
| CN-117567300-A | Synthesis method of gamma-amino alcohol containing continuous chiral center | 江苏大学 | 2024-02-20 | — | — | CN | claimed |
| CN-117567288-A | Method and process for preparing chiral secondary alcohol by asymmetric catalytic hydrogenation | 凯特立斯（深圳）科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114874134-B | Process for preparing nicotine in unprotected asymmetric way | 凯特立斯（深圳）科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-113527360-B | Phosphine-nitrogen ligand and application of complex thereof in catalyzing asymmetric reaction | 南方科技大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117247337-A | Method for asymmetrically synthesizing 1, 2-trans-amino alcohol and derivative thereof | 凯特立斯（深圳）科技有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117209382-A | Method and process for preparing chiral secondary alcohol by asymmetric catalytic hydrogenation | 凯特立斯（深圳）科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| US-7642291-B2 | O-acyloxime derivatives, preparation method thereof, and pharmaceutical composition containing the same for prevention and treatment of cardiovascular disease | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-01-05 | — | — | US | claimed |
| WO-2009054831-A1 | RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | NOVOLEN TECHNOLOGY HOLDINGS, C.V. (NL) | 2009-04-30 | — | — | WO | claimed |
| US-20050148776-A1 | Process for asymmetric hydrogenation of hexahydroquinoline salts | DSM IP ASSETS B.V. (NL) | 2005-07-07 | — | — | US | claimed |
| EP-1485357-B1 | PROCESS FOR ASYMMETRIC HYDROGENATION OF HEXAHYDROQUINOLINE SALTS | DSM IP ASSETS BV (NL) | 2005-07-06 | — | — | EP | claimed |
| EP-1485357-A1 | PROCESS FOR ASYMMETRIC HYDROGENATION OF HEXAHYDROQUINOLINE SALTS | DSM IP Assets B.V. (NL) | 2004-12-15 | — | — | EP | claimed |
| WO-2003078399-A1 | PROCESS FOR ASYMMETRIC HYDROGENATION OF HEXAHYDROQUINOLINE SALTS | DSM IP ASSETS B.V. (NL) | 2003-09-25 | — | — | WO | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| EP-0294937-B1 | NOVEL CINNAMOYLAMIDE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | claimed |
| US-4863963-A | 5-A-REDUCTASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | claimed |
| EP-0294937-A2 | Novel cinnamoylamide derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148776-A1 | Process for asymmetric hydrogenation of hexahydroquinoline salts | HRH1, HRH4, HRH2 | PTGS2 882/4885CA1 893/4885CA2 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.